US2020102382A1PendingUtilityA1
Compositions And Methods For Treating Cancer
Est. expiryJul 14, 2035(~8.9 yrs left)· nominal 20-yr term from priority
C12N 15/113C12N 15/1138C12N 2310/14C07K 16/24A61P 35/00C07K 2317/76A61K 39/39558A61K 2039/505G01N 33/574G01N 33/575G01N 33/57595G01N 2333/7158C12N 5/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express CCL20 and/or CCR6.
Claims
exact text as granted — not AI-modified1 . A method for inhibiting proliferation of a cancer stem cell (CSC) comprising contacting the CSC with an inhibitor of CCL20, an inhibitor of CCR6, or a combination thereof, in an amount effective to inhibit proliferation and/or reduce survival of the CSC.
2 . The method of claim 1 wherein the CSC expresses CCL20.
3 . The method of claim 1 wherein the CSC expresses CCR6.
4 . The method of claim 1 wherein the CSC is a sphere-forming CSC.
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . A method for treating a therapeutically-resistant cancer in a subject who has previously received a therapy and who is in need of treatment, comprising administering to the subject an inhibitor of CCL20, an inhibitor of CCR6, or a combination thereof, in an amount effective to treat the therapeutically-resistant cancer.
9 . The method of claim 8 wherein the CSCs express CCL20.
10 . The method of claim 8 wherein the CSCs express CCR6.
11 . The method of claim 8 wherein the CSCs comprise sphere-forming CSCs.
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . A method for treating a cancer that comprises cancer stem cells (CSCs), the method comprising administering to a subject in need of treatment an inhibitor of CCL20, an inhibitor of CCR6, or a combination thereof, in an amount effective to treat the cancer.
16 . The method of claim 15 wherein the CSCs express CCL20.
17 . The method of claim 15 wherein the CSCs express CCR6.
18 . The method of claim 15 wherein the CSCs comprise sphere-forming CSCs.
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . A method for treating cancer in a subject who has recurring or relapsed cancer comprising administering to a subject an inhibitor of CCL20, an inhibitor of CCR6, or a combination thereof, in an amount effective to treat the cancer.
23 . The method of claim 22 wherein the CSCs express CCL20.
24 . The method of claim 22 wherein the CSCs express CCR6.
25 . The method of claim 22 wherein the CSCs comprise sphere-forming CSCs.
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . (canceled)
53 . A method of determining the presence of a cancer stem cell (CSC) in a sample comprising cancer cells, the method comprising:
contacting the sample with an agent that binds to a CCL20 nucleic acid sequence or a CCL20 amino acid sequence; detecting the presence or absence of binding between the agent and the CCL20 nucleic acid sequence or the CCL20 amino acid sequence; and identifying the presence of the CSC in the sample upon detection of binding between the agent and the CCL20 nucleic acid sequence or the CCL20 amino acid sequence.
54 . The method of claim 53 , further comprising quantifying the amount of the CCL20 nucleic acid sequence or the CCL20 amino acid sequence in the sample, comparing the amount of the CCL20 nucleic acid sequence or the CCL20 amino acid sequence to a reference level of CCL20 nucleic acid or CCL20 amino acid, and identifying the presence of the CSC in the sample when the detected amount is greater than the reference level.
55 . The method of claim 53 , wherein the agent further comprises a detectable moiety.
56 . The method of claim 53 , wherein the agent comprises a nucleic acid sequence that hybridizes to the CCL20 nucleic acid sequence under stringent hybridization conditions.
57 . The method of claim 53 , wherein the agent comprises an antibody that specifically binds to the CCL20 amino acid sequence.
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . (canceled)
74 . (canceled)
75 . (canceled)
76 . (canceled)
77 . (canceled)
78 . (canceled)
79 . (canceled)
80 . (canceled)
81 . (canceled)
82 . (canceled)
83 . (canceled)
84 . (canceled)
85 . (canceled)
86 . (canceled)
87 . (canceled)
88 . (canceled)
89 . (canceled)
90 . (canceled)
91 . (canceled)
92 . (canceled)
93 . (canceled)Join the waitlist — get patent alerts
Track US2020102382A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.